EGCG联合化疗药物抗肿瘤的临床前研究进展  

Research Progress of EGCG as a Tumor Adjuvant Chemotherapeutic Drug in Preclinical Studies

作　　者：魏然 汪煜杭 陆发田 苏祝成[1] WEI Ran;WANG Yuhang;LU Fatian;SU Zhucheng(Tea Science Department,Zhejiang Agriculture and Forestry University,Hangzhou 311300,China;Chun'an County Jiukeng Lu Sheng Tea Professional Cooperatives,Chun'an 311700,China)

机构地区：[1]浙江农林大学茶学系,浙江杭州311300 [2]淳安县鸠坑陆圣茶叶专业合作社,浙江淳安311700

出　　处：《中国茶叶》2023年第4期6-14,共9页China Tea

基　　金：浙江省重点研发计划(2023C04028);杭州市博士创新站项目。

摘　　要：表没食子儿茶素没食子酸酯(EGCG)是绿茶多酚的主要组分,具有广谱抗癌活性。同时,多项研究表明,EGCG对多种化疗药物具有良好的增敏作用。文章分别对EGCG防治肺癌、乳腺癌、结肠癌、前列腺癌、胃癌等各类癌症及对5-氟尿嘧啶、阿霉素、二甲双胍、顺铂、紫杉醇等化疗药物的增敏作用进行了综述,为EGCG临床辅助治疗药物的开发提供理论依据。Epigallocatechin-3-gallate(EGCG)is a main ingredient of green tea polyphenols,with comprehensive anti-cancer effects.Meanwhile,EGCG has good sensitizing effects on various chemotherapeutic drugs in various studies.This article reviewed the anticancer activity of EGCG against various types of cancers such as lung cancer,breast cancer,colon cancer,prostate cancer,gastric cancer and its sensitizing effect on chemotherapeutic drugs such as 5-fluorouracil,doxorubicin,metformin,cisplatin and paclitaxel,respectively,so as to provide a theoretical basis for the development of EGCG as a clinical adjuvant drug.

关 键 词：表没食子儿茶素没食子酸酯 抗肿瘤 化疗药物 增敏 

分 类 号：Q946.841[生物学—植物学] R73[医药卫生—肿瘤]